Spots Global Cancer Trial Database for Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma
Official Title: An Expanded Access Program of Lifileucel, Autologous Tumor Infiltrating Lymphocytes (TIL; LN-144), for Patients With Unresectable or Metastatic Melanoma
Study ID: NCT05398640
Interventions
Study Description
Brief Summary: This is an open label, multi-center expanded access treatment protocol evaluating lifileucel (LN-144) in patients with unresectable or metastatic melanoma.
Detailed Description: Lifileucel (LN-144) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy that utilizes a 22-day centralized GMP process for the treatment of patients with advanced melanoma. Lifileucel is infused as part of a treatment regimen that includes preparative NMA-LD, followed by one-time autologous TIL infusion, and a short course of high-dose IL-2.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
HonorHealth Research and Innovation Institute, Scottsdale, Arizona, United States
Orlando Health Cancer Institute, Orlando, Florida, United States
University of Louisville - Brown Cancer Center, Louisville, Kentucky, United States
Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
The University of Tennessee Medical Center, Knoxville, Tennessee, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
